Annotation Detail
Information
- Associated Genes
- EREG
- Associated Variants
-
EREG EXPRESSION
EREG EXPRESSION - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoters (3-methylcholanthrene or control, butylated hydroxytoluene) was assessed in mice lacking Ereg (Ereg-/-) and wildtype controls (BALB/ByJ; Ereg+/+) at multiple time points and endpoints (bronchoalveolar lavage analysis, tumor analysis, mRNA expression, ELISA, wound assay). Initially a significantly reduced amount of inflammation (macrophages, PMNs) was observed in the Ereg-/- mice. At 20 wk, tumor multiplicity was also significantly decreased in the Ereg-/- mice.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1055
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1737
- Variant URL
- https://civic.genome.wustl.edu/links/variants/318
- Rating
- 2
- Evidence Type
- Prognostic
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Evidence Level
- E
- Clinical Significance
- Poor Outcome
- Pubmed
- 26894620
Drugs